Delivery Order SPE2DB24D3013-SPE2DB25FFLUG

Award Date 5/15/25
Potential Completion Date 5/16/25
Potential Value $8.4K
Ultimate Awardee
Not listed
Federal Contract Vehicle
Set-Aside Type
No Set-Aside Used
Extent Competed
Full and Open Competition
Major Defense Program
Not listed
Pricing Type
Firm Fixed Price
Place of Performance
Conshohocken, PA 19428, USA
Solicitation Procedures
Negotiated Proposal / Quote
Number Of Offers Received
Not listed
Legislative Mandate
Not listed
National Interest Action
Not listed
Research Type
Not listed
Primary Consortia Member
Not listed
Similar Awards
This is a delivery order contract awarded by the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract is for the provision of IBSRELA 50 MG TABLET UU 60S, a pharmaceutical product. The contract has a firm fixed price of $3,425.94 and a period of performance through May 15, 2025. Amerisourcebergen Drug Corp holds a larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, valued at...
This is a delivery order awarded by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor, for the supply of the medication IBSRELA 50 MG TABLET. The contract has a firm fixed price of $2,395.04 and a period of performance through April 2025. This order is part of a larger Indefinite Delivery Contract (IDC) held by AmerisourceBergen with DLA Troop Support Medical, valued at $999,999,999.00, which provides a comprehensive global pharmaceutical...
This is a delivery order contract awarded by the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp, a major pharmaceutical distributor, for the supply of IBSRELA 50 MG TABLET in 60-count units. The contract has a firm fixed price, with a ceiling value of $2,653.11, and an ultimate completion date of May 19, 2025. The contract is not set aside and is an open competition. Amerisourcebergen Drug Corp holds a significant Indefinite Delivery Contract (IDC) with the DLA Troop Support...
This is a delivery order contract awarded by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The $11,122.54 firm fixed-price contract is for the supply of IBSRELA 50 MG TABLET UU 60S medical products. The contract has an ultimate completion date of January 27, 2025 and was awarded on January 24, 2025. This award is under a larger Indefinite Delivery Contract (IDC) that AmerisourceBergen holds with the DLA...
This is a federal delivery order contract awarded by the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract is for the delivery of IBSRELA 50 MG TABLET UU 60S, a pharmaceutical product, with a ceiling value of $3,898.20 and a period of performance ending on May 12, 2025. The contract is a firm fixed-price, non-set-aside delivery order. Amerisourcebergen Drug Corp holds a larger Indefinite Delivery...
This is a firm fixed-price delivery order awarded by the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The $3,813.59 award is for the supply of IBSRELA 50 MG TABLET UU 60S, a medication product. The contract has a period of performance through May 14, 2025 and is not set aside for any specific business type. Amerisourcebergen Drug Corp holds a significant $999,999,999.00 Indefinite Delivery Contract (IDC) with...
This is a delivery order contract awarded by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor. The contract is for the delivery of the drug Ibsrela (50 mg tablet) with a ceiling value of $8,569.59 and a performance period ending on April 30, 2025. The contract is a firm fixed-price delivery order, which is not set aside for any specific business category. AmerisourceBergen Drug Corp holds a larger Indefinite Delivery Contract (IDC) with DLA...
This is a firm fixed-price delivery order issued by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor, for the provision of 4,567,943,153 units of the medication IBSRELA 50 MG TABLET. The contract has an ultimate completion date of April 17, 2025 and a ceiling value of $10,105.51. The contract is not set aside and is awarded as part of a larger Indefinite Delivery Contract (IDC) with a maximum value of $999,999,999.00, which provides...
This federal contract award was issued by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The $3,763.74 firm fixed-price delivery order is for the medical product "IBSRELA 50 MG TABLET UU 60S" with a completion date of February 28, 2025. AmerisourceBergen holds a $999,999,999 Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical, which serves as a primary vehicle for providing a...
This is a delivery order contract awarded by the Defense Logistics Agency (DLA) Troop Support Medical to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The $32,490.36 firm fixed-price contract is for the provision of 4566444867 IBSRELA 50 MG TABLET UU 60S medical supplies, and has an ultimate completion date of November 18, 2024. This award is not a set-aside contract. AmerisourceBergen holds a significant $999,999,999 Indefinite Delivery...
  • SPE2DB24D3013
    Indefinite Delivery Contract
  • SPE2DB24D3013-SPE2DB25FFLUG
    Delivery Order

This is a delivery order contract awarded by the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp, a major pharmaceutical distributor, to provide IBSRELA 50 MG TABLET UU 60S. The contract has a firm fixed price of $8,360.85 and a completion date of May 16, 2025. This delivery order is part of a larger Indefinite Delivery Contract (IDC) valued at $999,999,999.00 that Amerisourcebergen holds with the DLA Troop Support Medical division, which provides a comprehensive global pharmaceutical support vehicle through December 2026. The contract is not set-aside and is open to full and open competition.

Generated 8/17/25, 12:56 AM